Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test

Roche's ($RHHBY) Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer. Neither side is disclosing financial details. Specifically, they'll develop a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736, an anti-PD-L1 therapy. According to the companies, signals from PD-L1 help tumors avoid immune system detection. The idea is that MedImmune's treatment could combat this by targeting PD-L1, and Roche/Ventana will develop a test that screens for patients who may benefit most from the cancer immunotherapy. Release

Suggested Articles

Verily has obtained a second agency green light for measuring irregular heartbeats using its prescription smartwatch.

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.